Catherine S. Choong

Catherine S. Choong

Auto-generated profile, based on publicly available information

Catherine S. Choong

Department of Endocrinology and Diabetes , Perth Children’s Hospital , Perth , WA , Australia

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2017 in International Journal of Pediatric Endocrinology
Verified
Journal Article
Open access
PDF file
MAMary B. Abraham
Mary B. Abraham
DLDong Li
Dong Li
DTDave Tang
Dave Tang
SOSusan M. O’cOnnell
Susan M. O’cOnnell
FMFiona McKenzie
Fiona McKenzie
CCCatherine S. Choong
Catherine S. Choong
Hypoparathyroidism in children is a heterogeneous group with diverse genetic etiologies. To aid clinicians in the investigation and management of children with hypoparathyroidism, we describe the phenotype of a 6-year-old child with hypoparathyroidism and short stature diagnosed with Kenny-Caffey syndrome (KCS) Type 2 and the subsequent response to growth hormone (GH) treatment. The proband presented in the neonatal period with hypocalcemic seizures secondary to hypoparathyroidism. Her phenotype included small hands and feet, hypoplastic and dystrophic nails, hypoplastic mid-face and macrocrania. Postnatal growth was delayed but neurodevelopment was normal. A skeletal survey at 2 years of age was suggestive of KCS Type 2 and genetic testing revealed a novel de novo heterozygous mutation c.1622C > A (p.Ser541Tyr) in FAM111A. At 3 years and 2 months, her height was 80cms (SDS −3.86). She had normal overnight GH levels. GH therapy was commenced at a dose of 4.9 mg/m2/week for her short stature and low height velocity of 5cms/year. At the end of the first and second years of GH treatment, height velocity was 6.5cms/year and 7.2cms/year, respectively with maximal dose of 7.24 mg/m2/week. This case highlights the phenotype and the limited response to GH in a child with genetically proven KCS type 2. Long-term registries monitoring growth outcomes following GH therapy in patients with rare genetic conditions may help guide clinical decisions regarding the use and doses of GH in these conditions.

19 February 2016 in Obesity Science & Practice
Verified
Journal Article
Open access
PDF file
SRS. R. Rath
S. R. Rath
JMJ. A. Marsh
J. A. Marsh
JNJ. P. Newnham
J. P. Newnham
KZK. Zhu
K. Zhu
HAH. C. Atkinson
H. C. Atkinson
CCC. S. Choong
C. S. Choong
Summary: Objective: We examined parental and early‐life variables in order to identify risk factors for adulthood overweight and obesity in offspring. We report here on the longitudinal prevalence of overweight and obesity in Australian children born between 1989 and 1991 and followed from birth to age 22.Methods: Data were analysed on 1355 participants from the Western Australian Pregnancy Cohort (Raine) Study, with anthropometry collected during pregnancy, at birth, one year and at three yearly intervals thereafter. Multivariate analyses and cross‐sectional logistic regression quantified the timing and contribution of early‐life risk factors for overweight and obesity in young‐adulthood.Results: At five years of age 12.6% of children were overweight and 5.2% were obese. By early adulthood, the prevalence of obesity had increased to 12.8%, whilst overweight remained relatively stable at 14.2% (range from early childhood to adulthood 11–16%). Parental pre‐pregnancy body mass index (BMI) was the strongest determinant of adult offspring BMI. Although rapid first year weight gain was associated with increased offspring BMI, the impact of first year weight‐gain diminished over childhood, whilst the impact of parental BMI increased over time.Conclusions: Parental pre‐pregnancy BMI and rapid early‐life weight gain predispose offspring to obesity in adulthood.

1 March 2010 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
IHIan P. Hughes
Ian P. Hughes
CCCatherine S. Choong
Catherine S. Choong
ACAndrew Cotterill
Andrew Cotterill
MHMark Harris
Mark Harris
PDPeter Davies
Peter Davies
Background: About twice as many boys than girls are treated with GH. Ascertainment bias is a possible explanation. Hypotheses: For ascertainment bias, the gender least frequently treated should be relatively shorter, and in an unbiased population sample, equal numbers of boys and girls should be eligible for GH treatment. Subjects and Setting: In 2007 a total of 1485 Australian children received GH (OZGROW database). Heights were also obtained from two recent unbiased surveys consisting of 3596 and 4794 Australian children. Methods: Numbers of boys and girls treated with GH were determined for each treatment indication. Height sd scores (SDS) at first presentation for GH-treated boys and girls were assessed. Frequency of boys and girls from two unbiased populations with height SDS less than −2.326 were recorded. Outcomes: Outcomes included gender frequencies and height SDSs. Hypotheses were formed before interrogation of preexisting databases. Results: More boys than girls received GH (P = 3.68 × 10−20). By indication: biochemical GH deficiency (P = 0.001), cranial irradiation (P = 0.002), slow growing (P = 2.09 × 10−16), and chronic renal failure (P = 0.061). Approximately equal numbers of girls and boys were treated for hypoglycemia (P = 0.543). Slow-growing girls were relatively shorter than boys for ages spanning 4.50–8.49 yr (P = 3.80 × 10−4), but boys were relatively shorter in the 6.00- to 17.99-month age group (P = 0.011). Biochemical boys were relatively shorter than girls (P = 0.023). In the two unbiased surveys, boys outnumbered girls 11 to six and 16 to eight for height SDS less than −2.326. Conclusions: There is a gender bias in this GH-treated population. Ascertainment bias does not appear to be the major cause.

2 March 2018 in International Journal of Pediatric Endocrinology
Verified
Journal Article
Open access
PDF file
KRKaren M. Rothacker
Karen M. Rothacker
KAKatie L Ayers
Katie L Ayers
DTDave Tang
Dave Tang
KJKiranjit Joshi
Kiranjit Joshi
JBJocelyn A. van Den Bergen
Jocelyn A. van Den Bergen
CCCatherine S. Choong
Catherine S. Choong
Desert hedgehog (DHH) mutations have been described in only a limited number of individuals with 46, XY disorders of sex development (DSD) presenting as either partial or complete gonadal dysgenesis. Gonadal tumours and peripheral neuropathy have been associated with DHH mutations. Herein we report a novel, homozygous mutation of DHH identified through a targeted, massively parallel sequencing (MPS) DSD panel, in a patient presenting with partial gonadal dysgenesis. This novel mutation is two amino acids away from a previously described mutation in a patient who presented with complete gonadal dysgenesis. Adding to the complexity of work-up, our patient also expressed gender identity concern. A 14-year-old, phenotypic female presented with primary amenorrhoea and absent secondary sex characteristics. Investigations revealed elevated gonadotrophins with low oestradiol, testosterone of 0.6 nmol/L and a 46, XY karyotype. Müllerian structures were not seen on pelvic ultrasound or laparoscopically and gonadal biopsies demonstrated dysgenetic testes without neoplasia (partial gonadal dysgenesis). The patient expressed gender identity confusion upon initial notification of investigation findings. Formal psychiatric evaluation excluded gender dysphoria. Genetic analysis was performed using a targeted, MPS DSD panel of 64 diagnostic and 927 research candidate genes. This identified a novel, homozygous mutation in exon 2 of DHH (DHH:NM_021044:exon2:c.G491C:p.R164P). With this finding our patient was screened for the possibility of peripheral neuropathy which was not evident clinically nor on investigation. She was commenced on oestrogen for pubertal induction. The evaluation of patients with DSD is associated with considerable psychological distress. Targeted MPS enables an affordable and efficient method for diagnosis of 46, XY DSD cases. Identifying a genetic diagnosis may inform clinical management and in this case directed screening for peripheral neuropathy. In addition to the structural location of the mutation other interacting factors may influence phenotypic expression in homozygous DHH mutations.

1 January 2015 in Journal of Pediatric Endocrinology and Metabolism
Verified
Journal Article
Closed access
MAMary B. Abraham
Mary B. Abraham
VSVinutha B. Shetty
Vinutha B. Shetty
GPGlynis Price
Glynis Price
NSNicholas Smith
Nicholas Smith
MBMartin de Bock
Martin de Bock
CCCatherine S. Choong
Catherine S. Choong
Hyperinsulinaemic hypoglycaemia (HH) is characterised by inappropriate insulin secretion and is the most common cause for persistent neonatal hypoglycaemia. The only treatment available for medically unresponsive hypoglycaemia is a near-total pancreatectomy. A neonate with severe HH, due to a homozygous ABCC8 mutation, was not responsive to treatment with maximal doses of diazoxide and subcutaneous daily octreotide, and underwent a near-total pancreatectomy; however, hypoglycaemia persisted. Introduction of sirolimus, an mTOR (mammalian target of rapamycin) inhibitor, obviated the requirement for glucose infusion. Euglycaemia was achieved with no significant adverse events from the drug. Sirolimus therapy was ceased at 13 months of age. No episodes of persistent hypoglycaemia were observed after cessation of sirolimus. This report demonstrates the successful use of sirolimus for persistent hypoglycaemia in the critically ill infant post pancreatectomy. Sirolimus could be considered in patients with severe HH not responsive to conventional medical and surgical therapy. However, the long-term efficacy and safety with this immunosuppressive drug in very young patients are not assured.

20 June 2014 in International Journal of Pediatric Endocrinology
Verified
Journal Article
Open access
PDF file
MAMary B Abraham
Mary B Abraham
SRShripada Rao
Shripada Rao
GPGlynis Price
Glynis Price
CCCatherine S Choong
Catherine S Choong
The treatment of central diabetes insipidus (DI) with desmopressin in the neonatal period is challenging because of the significant risk of hyponatremia with this agent. The fixed anti-diuresis action of desmopressin and the obligate high fluid intake with milk feeds lead to considerable risk of water intoxication and hyponatremia. To reduce this risk, thiazide diuretics, part of the treatment of nephrogenic DI, were used in conjunction with low renal solute feed and were effective in a single case series of neonatal central DI.